psalexa
logo

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: March 2017
Report Code: LS10796
Available Format:
Pages: 173

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

This report includes the Estrogen Receptor-Positive (ER+) breast cancer pipeline analysis as of 2017, to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to ER+ breast cancer.

ER+ Breast Cancer Pipeline Analysis

  • By phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical

Note: In the pipeline analysis, inactive and discontinued products have been analyzed separately.

  • By route of administration
    • Oral
    • Intravenous
    • Subcutaneous
  • By target
    • Phosphatidylinositol-3-Kinase (PI3K)
    • Mammalian Target of Rapamycin (mTOR)
    • Bromodomain and Extra-Terminal (BET)
    • Cyclin-Dependent Kinases (CDK)
    • Histone Deacetylase (HDAC)
    • Others
  • By company

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 6000

Pre-Purchase Enquiry